Diagnosis and treatment of invasive aspergillosis
AssigneesThe Brigham and Women's Hospital, Inc., The Charles Stark Draper Laboratory, Inc.
InventorsSophia Koo, Horatio R. Thomas, James Constantine Comolli, Preshious Rearden, Lindsey R. Baden, Francisco M. Marty
Life of this patent
Estimating the term…
Abstract
Methods for diagnosing, treating, and monitoring the treatment of invasive aspergillosis (IA) are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having IA.
Claims23
A method for treating a subject with invasive aspergillosis (IA), the method comprising:
- obtaining a sample from a subject;
- detecting the presence in the sample of one, two, three, or more volatile organic compounds (VOCs) produced by the Aspergillus species in a sample, wherein the VOCs are selected from the group consisting of farnesene, beta-vatirenene, cis-geranylacetone, camphene, alpha-pinene, beta-pinene, limonene, alpha-bergamotene, farnesene, elixene, alpha-santalene, beta-elemene, acoradien, chamigrene, 1,5,9-trimethyl cyclododecatriene, 9-decene-2-one and beta-sesquiphellandrene;
- and
- administering a treatment to a subject when there are one, two, three or more of the VOCs present in the sample.
(canceled)
A method of monitoring efficacy of a treatment for invasive aspergillosis (IA) in a subject, the method comprising:
- determining a first level of one, two, three, or more volatile organic compounds (VOCs) produced by the Aspergillus species in a sample comprising breath from the subject or headspace from a culture suspected of comprising Aspergillus isolated from the subject, wherein the VOCs are selected from the group consisting of farnesene, beta-vatirenene, cis-geranylacetone, camphene, alpha-pinene, beta-pinene, limonene, alpha-bergamotene, farnesene, elixene, alpha-santalene, beta-elemene, acoradien, chamigrene, 1,5,9-trimethyl cyclododecatriene, 9-decene-2-one and beta-sesquiphellandrene, in the subject;
- administering a treatment for IA to the subject;
- determining a second level of the VOCs in a sample obtained after administration of the treatment to the subject;
- and
- comparing the first and second levels of VOCs, wherein a decrease in the VOCs indicates that the treatment has been effective in treating the IA in the subject, and an increase or no change indicates that the treatment has not been effective in treating the IA in the subject.
A method of identifying a candidate compound for the treatment of IA, the method comprising:
- providing a test culture comprising one or more Aspergillus species;
- detecting a baseline level of fungal volatile organic compounds (VOCs) in the headspace of the culture in the absence of the test compound, wherein the VOCs are selected from the group consisting of farnesene, beta-vatirenene, cis-geranylacetone, camphene, alpha-pinene, beta-pinene, limonene, alpha-bergamotene, farnesene, elixene, alpha-santalene, beta-elemene, acoradien, chamigrene, 1,5,9-trimethyl cyclododecatriene, 9-decene-2-one and beta-sesquiphellandrene;
- contacting the test culture with a test compound;
- determining a second level of the VOCs in a the test culture;
- comparing the second level of VOCs to the baseline level;
- and
- identifying a test compound that decreases levels of fungal VOCs in the test culture as a candidate compound for the treatment of IA.
10-11. (canceled)
(canceled)
Dependencies are inferred from the claim text.